Meriofert Set

Follicle-Stimulating Hormone, the active ingredient in Meriofert Set, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is employed to stimulate follicular development and ovulation in women experiencing anovulatory infertility. GNH USA supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Set, a gonadotropin used in reproductive medicine, addresses several infertility‑related conditions. - Anovulatory infertility: promotes follicular growth and induces ovulation. - Controlled ovarian stimulation for IVF/ICSI: enhances the number of mature oocytes retrieved. - Ovulation induction in polycystic ovary syndrome: restores regular ovulatory cycles.

Adverse reactions may occur with any gonadotropin therapy.

Common Side Effects: - Injection site pain or erythema - Mild abdominal discomfort or bloating - Headache - Nausea - Transient mild ovarian hyperstimulation syndrome

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome (OHSS) - Thromboembolic events - Allergic or anaphylactic reactions - Pulmonary edema - Ectopic pregnancy

Careful patient assessment and monitoring are essential when using Meriofert Set. - Pregnancy testing: confirm the patient is not pregnant before initiating therapy. - Ovarian monitoring: perform serial ultrasound to evaluate follicular response. - Thromboembolic risk: assess history of clotting disorders and monitor for signs of thrombosis. - Allergy: avoid use in individuals with known hypersensitivity to gonadotropins. - Drug interactions: review concomitant medications that may affect ovarian response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Set may interact with several medications that influence hormonal pathways or clotting risk.

Major Interactions (Avoid): - GnRH antagonists: may blunt the intended ovarian response. - Oral contraceptives: suppress endogenous gonadotropin release, reducing efficacy. - High‑dose estrogen therapy: can counteract the action of administered gonadotropins.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased risk of thrombosis if severe OHSS develops. - Insulin or oral hypoglycemics: monitor glucose levels during OHSS. - Thyroid hormone therapy: adjust dosing if significant hormonal fluctuations occur.